Searched for
ORGAN TRANSPLANT DRUG
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- Concord Biotech shares jump 8% on USFDA nod for Mycophenolate Mofetil oral suspensionConcord Biotech shares saw a significant jump on Wednesday. This surge followed the company's announcement of receiving approval from the U...
- Good news for diabetes & BP patients: Govt cuts prices of these 30 medicines, relief may reach pharmacies soonThe National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 essential drug formulations, including those for diabet...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Natco Pharma acquires 40 million shares in eGenesis IncNatco Pharma's Canadian subsidiary has acquired 40 million shares in eGenesis Inc. for USD 8 million. eGenesis is a biotechnology company d...
- Animal to human organ transplants possible? Here's what scientists claimScientists have said that they are closer to comprehending the best way to turn the human body reactive to an organ donation from another s...
- Second recipient of pig heart transplant dies after nearly six weeksA 58-year-old man named Lawrence Faucette, who was suffering from heart failure and disqualified from a conventional heart transplant, unde...
- 8-year-old girl gets UK's first kidney transplant without need for life-long drugs. What we know so farEight-old-girl Aditi Shankar became the first person in the UK to get a kidney transplant without needing to get life-long drugs. How did t...
- Lupin launches generic drug used for prevention of organ rejection in kidney transplant in USDrug firm Lupin on Monday said it has launched generic Mycophenolic acid delayed-release tablets, which is used to prevent organ rejection ...
- Zydus Cadila gets USFDA nod for Mycophenolate MofetilThe approval is for Mycophenolate Mofetil injection of strength 500mg/vial, the company said in a BSE filing.
- Zydus Group clinches in-licensing deal with Swiss company Neovii"The Zydus group will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant med...
- Mastering multi-organ transplants to save the critically illA week ago, doctors at a private hospital in Kerala did an elbow-level double hand transplant for a 22-year-old whose hands were burned.
- Why xenotransplants through pigs are making headlinesBelieve it or not, pigs might soon extend the lives of people waiting for organ donations.
- Who can donate organs in India, when and howFor organ recipients, a transplant often means a second chance at life. Vital organs such as the heart, pancreas, liver, kidneys and lungs ...
- US doctors perform historic skull-scalp transplantWorld's first skull-scalp transplant was performed by American surgeons on a man who suffered a large head wound from cancer treatment.
- Give your heart away: India learnt to donate blood, it must do the same with liver, kidneys, lungs and heartThe new Transplantation of Human Organs Act aimed to stop organ trading and to make transplantation affordable for the poor and middle clas...
- Zydus Cadila gets USFDA nod to sell drugs in the US market"Zydus Cadila received the final approval from the USFDA to market Sirolimus tablets 0.5 mg with 180 days of marketing exclusivity,"
- Panacea Biotech enters into pact with Kremers Urban; stock upShares of Panacea Biotech gained momentum after the company entered into strategic alliance with Kremers Urban for 11 high barrier to entry...
- Laboratorios to market Panacea drug in EuropePanacea Biotec has signed a non-exclusive marketing agreement with Uruguay's Laboratorios Clausen SA, allowing the Latin American firm to m...
- Astellas aims to emerge top player in transplantationJapan’s second-largest pharma company, the $10-billion Astellas Pharma, intends to emerge as a niche player in India.
Load More
